General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Eidos, Inc(MODEST), Novo Nordisk Inc.(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Bridge Bio(MODEST), Attralus(MODEST), Ionis(MODEST) RESEARCH/RESEARCH GRANTS: Alnylam Inc(MODEST)

View Full Disclosure